John D. Horowitz

List of Publications by Year
in descending order

149 papers	14,910 citations	76326 40 h-index	18647 119 g-index
152 all docs	152 docs citations	152 times ranked	13890 citing authors

#	Article	IF	Citations
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	27.0	7,537
2	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal, 2018, 39, 2032-2046.	2.2	972
3	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. European Heart Journal, 2018, 39, 2047-2062.	2.2	521
4	Apixaban for Reduction In Stroke and Other ThromboembоLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	2.7	407
5	Metabolic Modulation With Perhexiline in Chronic Heart Failure. Circulation, 2005, 112, 3280-3288.	1.6	322
6	Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616.	1.6	298
7	The Coronary Slow Flow Phenomenon â€“ A New Coronary Microvascular Disorder. Cardiology, 2002, 97, 197-202.	1.4	237
8	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
9	Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 174, 696-701.	1.7	207
10	Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochemical Pharmacology, 1996, 52, 273-280.	4.4	204
11	Meta-Analysis of Clinical Correlates of Acute Mortality in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1420-1428.	1.6	175
12	Perhexiline. Cardiovascular Drug Reviews, 2007, 25, 76-97.	4.1	152
13	Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. American Heart Journal, 2003, 146, 84-90.	2.7	151
14	Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. European Heart Journal, 2004, 25, 634-641.	2.2	148
15	The Deleterious Effects of Hyperglycemia on Platelet Function in Diabetic Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 49, 304-310.	2.8	138
16	N -Acetylcysteine in Combination With Nitroglycerin and Streptokinase for the Treatment of Evolving Acute Myocardial Infarction. Circulation, 1995, 92, 2855-2862.	1.6	135
17	N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1316-1321.	1.6	123
18	Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segmentâ€“Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation, 2017, 136, 894-903.	1.6	108

#	Article	IF	Citations
19	The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. Journal of the American College of Cardiology, 2004, 44, 57-62.	2.8	102
20	Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart, 2012, 98, 1278-1284.	2.9	100
21	An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 42-50.	2.3	91
22	Alterations in Cardiac Deformation, Timing ofÂContraction and Relaxation, and Early Myocardial Fibrosis Accompany the Apparent Recovery of Acute Stress-Induced (Takotsubo) Cardiomyopathy: An End to the Concept ofÂTransience. Journal of the American Society of Echocardiography, 2017, 30, 745-755.	2.8	91
23	Nitrate Resistance In Platelets From Patients With Stable Angina Pectoris. Circulation, 1999, 100, 129-134.	1.6	87
24	Impaired tissue responsiveness to organic nitrates and nitric oxide: A new therapeutic frontier?. , 2007, 116, 287-305.		87
25	Determination of l-arginine and NG,NG- and NG,NGâ€²-dimethyl-l-arginine in plasma by liquid chromatography as AccQ-Fluorâ„¢ fluorescent derivatives. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 325-329.	2.3	86
26	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	79
27	Platelet Nitric Oxide Responsiveness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2661-2666.	2.4	76
28	Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes. Cardiovascular Drugs and Therapy, 2014, 28, 347-360.	2.6	76
29	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
30	Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. Journal of the American College of Cardiology, 2001, 37, 1851-1857.	2.8	73
31	Aging of the Nitric Oxide System: Are We as Old as Our NO?. Journal of the American Heart Association, 2014, 3, .	3.7	67
32	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102, 508-517.	2.9	67
33	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	3.7	63
34	Tako-Tsubo Cardiomyopathy: A Heart Stressed Out of Energy?. JACC: Cardiovascular Imaging, 2015, 8, 985-987.	5.3	57
35	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
36	Cangrelor With and Without GlycoproteinÂIIb/IIIa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47

#	Article	IF	Citations
37	Modulation of myocardial metabolism: an emerging therapeutic principle. Current Opinion in Cardiology, 2010, 25, 329-334.	1.8	46
38	Ramipril Sensitizes Platelets to Nitric Oxide. Journal of the American College of Cardiology, 2012, 60, 887-894.	2.8	46
39	Occurrence of Tako-Tsubo Cardiomyopathy in Association with Ingestion of Serotonin/Noradrenaline Reuptake Inhibitors. Heart Lung and Circulation, 2012, 21, 203-205.	0.4	45
40	Dissociation Between Severity of Takotsubo Cardiomyopathy and Presentation With Shock or Hypotension. Clinical Cardiology, 2013, 36, 401-406.	1.8	45
41	Relation of Delayed Recovery of Myocardial Function After Takotsubo Cardiomyopathy to Subsequent Quality of Life. American Journal of Cardiology, 2015, 115, 1085-1089.	1.6	43
42	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42
43	Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. European Journal of Pharmacology, 2006, 531, 13-19.	3.5	39
44	Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. American Journal of Cardiology, 2002, 90, 551-554.	1.6	38
45	Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy. International Journal of Cardiology, 2013, 168, 4624-4630.	1.7	36
46	Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. JACC Basic To Translational Science, 2018, 3, 213-226.	4.1	36
47	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. British Journal of Pharmacology, 2011, 162, 722-732.	5.4	35
48	Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure. Drugs, 2016, 76, 1337-1348.	10.9	35
49	Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. International Journal of Cardiology, 2017, 243, 296-299.	1.7	35
50	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	2.4	34
51	Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?. Cardiovascular Drugs and Therapy, 2013, 27, 541-547.	2.6	32
52	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 721-733.	2.8	31
53	Dissociation of Early Shock in Takotsubo Cardiomyopathy from either Right or Left Ventricular Systolic Dysfunction. Heart Lung and Circulation, 2014, 23, 1141-1148.	0.4	27
54	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	3.7	27

#	Article	IF	Citations
55	Homoarginine and 3-nitrotyrosine in patients with takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 173, 546-547.	1.7	26
56	Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. International Journal of Cardiology, 2015, 179, 160-165.	1.7	24
57	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	7.1	24
58	Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. British Journal of Clinical Pharmacology, 2005, 60, 355-363.	2.4	22
59	Drugs that Affect Cardiac Metabolism: Focus on Perhexiline. Cardiovascular Drugs and Therapy, 2016, 30, 399-405.	2.6	21
60	Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 520-525.	3.0	20
61	Prediction of shortâ€and longâ€term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
62	Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Review of Cardiovascular Therapy, 2012, 10, 215-221.	1.5	19
63	Hypoxic potentiation of nitrite effects in human vessels and platelets. Nitric Oxide - Biology and Chemistry, 2014, 40, 36-44.	2.7	19
64	Nitric Oxide Resistance, Induced in the Myocardium by Diabetes, Is Circumvented by the Nitric Oxide Redox Sibling, Nitroxyl. Antioxidants and Redox Signaling, 2020, 32, 60-77.	5.4	18
65	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	3.7	18
66	Assessment of Artificial Intelligence in Echocardiography Diagnostics in Differentiating Takotsubo Syndrome From Myocardial Infarction. JAMA Cardiology, 2022, 7, 494.	6.1	18
67	New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?. Heart Rhythm, 2016, 13, 1355-1361.	0.7	16
68	Inorganic nitrate and nitrite supplementation fails to improve skeletal muscle mitochondrial efficiency in mice and humans. American Journal of Clinical Nutrition, 2020, 111, 79-89.	4.7	16
69	Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling. Frontiers in Pharmacology, 2020, 11, 727.	3.5	15
70	The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome. Contemporary Clinical Trials, 2020, 90, 105894.	1.8	14
71	Serial measurement of interleukinâ€6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and REâ€LY trials. Journal of Thrombosis and Haemostasis, 2020, 18, 2287-2295.	3.8	14
72	Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). American Heart Journal, 2021, 240, 101-113.	2.7	14

#	Article	IF	Citations
73	Amelioration of nitrate tolerance: matching strategies with mechanisms**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 2001-2003.	2.8	13
74	Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine. Pharmacological Research, 2009, 60, 503-507.	7.1	13
75	Emerging drugs for the treatment of angina pectoris. Expert Opinion on Emerging Drugs, 2016, 21, 365-376.	2.4	13
76	Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults. PLoS ONE, 2017, 12, e0174435.	2.5	13
77	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. Journal of Thrombosis and Thrombolysis, 2019, 47, 345-352.	2.1	13
78	Takotsubo Syndrome: Finally Emerging From the Shadows?. Heart Lung and Circulation, 2021, 30, 36-44.	0.4	13
79	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. Scientific Reports, 2021, 11, 23555.	3.3	13
80	Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 1042.	4.1	13
81	Takotsubo cardiomyopathy presenting as Sâ€“T elevation myocardial infarction: Not gone but forgotten?. International Journal of Cardiology, 2014, 172, e261-e262.	1.7	12
82	Role of aldehyde dehydrogenase in hypoxic vasodilator effects of nitrite in rats and humans. British Journal of Pharmacology, 2015, 172, 3341-3352.	5.4	12
83	Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit. Therapeutic Drug Monitoring, 2016, 38, 73-78.	2.0	12
84	The Heart Failure with Preserved Ejection Fraction Conundrumâ€”Redefining the Problem and Finding Common Ground?. Current Heart Failure Reports, 2020, 17, 34-42.	3.3	12
85	Suppression of neutrophil superoxide generation by <scp>BNP</scp> is attenuated in acute heart failure: a case for â€˜<scp>BNP</scp> resistanceâ€™. European Journal of Heart Failure, 2015, 17, 475-483.	7.1	11
86	Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trial. Trials, 2016, 17, 18.	1.6	11
87	Platelet hyperaggregability in patients with atrial fibrillation. Herz, 2016, 41, 57-62.	1.1	11
88	Inorganic Nitrate in Angina Study: A Randomized Doubleâ€Blind Placeboâ€Controlled Trial. Journal of the American Heart Association, 2017, 6, .	3.7	11
89	Impairment of platelet NO signalling in coronary artery spasm: role of hydrogen sulphide. British Journal of Pharmacology, 2021, 178, 1639-1650.	5.4	11
90	Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. European Journal of Pharmacology, 1998, 356, 207-213.	3.5	10

#	Article	IF	Citations
91	Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2010, 24, 131-137.	2.6	10
92	Interaction of Terbinafine (Anti-fungal agent) with Perhexiline: A Case Report. Heart Lung and Circulation, 2014, 23, e149-e151.	0.4	10
93	Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium. European Journal of Clinical Pharmacology, 2015, 71, 1485-1491.	1.9	10
94	Attenuation of the Negative Inotropic Effects of Metoprolol at Short Cycle Lengths in Humans. Journal of the American College of Cardiology, 2006, 48, 1234-1241.	2.8	9
95	Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1â€“7) is associated with suppression of superoxide release. Platelets, 2007, 18, 158-164.	2.3	9
96	Panic disorder and incident coronary heart disease: a systematic review and meta-analysis protocol. Systematic Reviews, 2015, 4, 33.	5.3	9
97	Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach. Scientific Reports, 2020, 10, 20537.	3.3	9
98	The Antianginal Drug Perhexiline Displays Cytotoxicity against Colorectal Cancer Cells In Vitro: A Potential for Drug Repurposing. Cancers, 2022, 14, 1043.	3.7	9
99	Bâ€Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 739-743.	1.9	8
100	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. Thrombosis Research, 2015, 136, 308-314.	1.7	8
101	New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications. Cardiovascular Drugs and Therapy, 2016, 30, 505-513.	2.6	8
102	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
103	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	3.3	8
104	Risk stratification for coronary artery disease in multi-ethnic populations: Are there broader considerations for cost efficiency?. World Journal of Methodology, 2019, 9, 1-19.	3.5	8
105	Tolerance Induction During Therapy with Long-Acting Nitrates: How Extensive is the â€œCollateral Damageâ€?. Cardiovascular Drugs and Therapy, 2004, 18, 11-12.	2.6	7
106	Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NOâ€¢) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation. Handbook of Experimental Pharmacology, 2020, 264, 311-337.	1.8	7
107	Angina due to coronary artery spasm (variant angina): diagnosis and intervention strategies. Expert Review of Cardiovascular Therapy, 2021, 19, 917-927.	1.5	7
108	Heart failure in older people: the epidemic we had to have. Medical Journal of Australia, 2001, 174, 432-433.	1.7	6

#	Article	IF	Citations
109	Reversal of Hyperglycemia: Effects on Nitric Oxide Signaling. American Journal of Medicine, 2015, 128, 427-430.	1.5	6
110	Neutrophil-Initiated Myocardial Inflammation and Its Modulation by B-Type Natriuretic Peptide: A Potential Therapeutic Target. International Journal of Molecular Sciences, 2019, 20, 129.	4.1	6
111	Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. Heart and Vessels, 2020, 35, 197-206.	1.2	6
112	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.	3.0	6
113	Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality. Cardio-Oncology, 2019, 5, 20.	1.7	5
114	Platelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation. Mediators of Inflammation, 2016, 2016, 1-5.	3.0	4
115	A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS. Future Cardiology, 2016, 12, 617-626.	1.2	4
116	Matrix metalloproteinase-2 activation: critical to myocardial contractile dysfunction following ischaemiaâ€“reperfusion. Cardiovascular Research, 2020, 116, 876-878.	3.8	4
117	Does high on-treatment platelet aggregability reflect poor individual response to clopidogrel?. Thrombosis Research, 2020, 196, 510-515.	1.7	4
118	Incremental â€œTherapeuticâ€•Myocardial Exposure to Catecholamines: Incidence and Impact in Takotsubo Syndrome. Cardiovascular Drugs and Therapy, 2020, 34, 95-100.	2.6	4
119	Incidence and clinical/laboratory correlates of early hypotension in takotsubo syndrome. ESC Heart Failure, 2021, 8, 2009-2015.	3.1	4
120	Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. Journal of Geriatric Cardiology, 2016, 13, 202-8.	0.2	4
121	Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance. British Journal of Pharmacology, 2022, 179, 4117-4135.	5.4	4
122	Transdiagnostic Cognitive-Behavioral Therapy for Depression and Anxiety Disorders in Cardiovascular Disease Patients: Results From the CHAMPS Pilot-Feasibility Trial. Frontiers in Psychiatry, 2022, 13, 741039.	2.6	4
123	Is there still a role for treatment with Î²-adrenoceptor antagonists in post-myocardial infarction patients with well-preserved left ventricular systolic function?. Acute Cardiac Care, 2008, 10, 144-147.	0.2	3
124	Role of Echocardiography in Tako-Tsubo Cardiomyopathy. JACC: Cardiovascular Imaging, 2014, 7, 130-132.	5.3	3
125	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2017, 227, 443-449.	1.7	3
126	Does cardiac resynchronization therapy restore peripheral circulatory homeostasis?. ESC Heart Failure, 2018, 5, 129-138.	3.1	3

#	Article	IF	Citations
127	ADAM-15 and glycocalyx shedding: a new perspective on sepsis-related vasomotor dysfunction. Cardiovascular Research, 2018, 114, 1694-1695.	3.8	3
128	Editorial Commentary: Takotsubo syndrome: A key role for inflammation?. Trends in Cardiovascular Medicine, 2021, 31, 231-232.	4.9	3
129	Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice. Current Cardiology Reviews, 2021, 17, e160721187934.	1.5	3
130	The unspoken benefit of participation in a clinical trial. Clinical Medicine, 2021, 21, e645-e647.	1.9	3
131	Early treatment with verapamil or diltiazem in patients with acute myocardial infarction: safety and possible beneficial effects. Cardiovascular Drugs and Therapy, 1999, 13, 309-314.	2.6	2
132	Can We Improve Long-Term Outcomes Postbifurcation Stenting by Prolonged Dual Antiplatelet Therapy?. Circulation: Cardiovascular Interventions, 2018, 11, e006922.	3.9	2
133	Electrical remodelling post cardiac resynchronization therapy in patients with ischemic and non-ischemic heart failure. Journal of Electrocardiology, 2019, 53, 44-51.	0.9	2
134	Prolonged suppression of the antiâ€oxidant/antiâ€inflammatory effects of BNP postâ€Takotsubo syndrome. ESC Heart Failure, 2020, 7, 2250-2257.	3.1	2
135	The Prevalence of ST-Segment Depression on Ambulatory Electrocardiographic Monitoring During Daily Life in High-Risk Asymptomatic Police Officers. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 143-148.	2.8	1
136	Author's Reply. Journal of the American Society of Echocardiography, 2017, 30, 1042.	2.8	1
137	Interactions Between Influenza and Heart Failure Hospitalizationsâ€"Diagnostic and Pathogenetic Issues. JAMA Cardiology, 2019, 4, 949.	6.1	1
138	Increased Rate of Hospitalization With Prinzmetal Angina: What Exactly Is Happening?. American Journal of Medicine, 2020, 133, e162-e163.	1.5	1
139	Approaches for Overcoming Diabetes-Induced Cardiovascular Nitric Oxide Resistance. Free Radical Biology and Medicine, 2016, 100, S150-S151.	2.9	0
140	N-ACETYLCYSTEINE REVERSES PEROXYNITRITE AND HYDROGEN PEROXIDE-INDUCED APOPTOSIS OF HUMAN MYOCARDIAL CELLS. Journal of the American College of Cardiology, 2019, 73, 1022.	2.8	0
141	Takotsubo Syndrome Identified in the Intensive Care Unit: A Prospective Observational Study. Australian Critical Care, 2019, 32, S17.	1.3	0
142	Diabetes-induced myocardial NOâ€¢ resistance, is circumvented by the nitric oxide (NO) redox sibling, nitroxyl, HNO. Journal of Molecular and Cellular Cardiology, 2020, 140, 9.	1.9	0
143	Letter by Nguyen et al Regarding Article, â€œCoronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Womenâ€. Circulation, 2021, 144, e205.	1.6	0
144	Report from the Annual Conference of the British Society of Echocardiography, November 2016, Queen Elizabeth II Conference Centre, LondonForewordNational Invited Lecture 2016Echo Research and Practice sessionAbstract 1: Left ventricular mechano-temporal alterations during the apparent recovery of acute stress-induced (Tako-tsubo) cardiomyopathyAbstract 2: Right ventricular structure and function in veteran ultrarunners: is there evidence for chronic maladaptation?Abstract 3: Feasibility, efficacy and safety. Journal of Animal Science and Technology, 2017, 4, M1-M18.	2.5	0

#	Article	IF	Citations
145	Signal transduction pathways initiated by catecholamines in takotsubo syndrome: focus on nitrosative stress and energetic impairment. , 2018, , 1283-1286.		0
146	Risk indexation and atrial fibrillation. Aging, 2019, 11, 1607-1608.	3.1	0
147	Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. American Journal of Cardiovascular Disease, 2015, 5, 101-9.	0.5	0
148	Abstract P405: Cardioprotective Actions Of Nitroxyl Donor Angeli's Salt Are Preserved In The Diabetic Heart And Vasculature In The Face Of Nitric Oxide Resistance. Circulation Research, 2021, 129, .	4.5	0
149	Contextualising evidence based medicine in determining the key root for translational effectiveness for chronic disease self-management and heart failure. Reviews in Cardiovascular Medicine, 2022, 23, 1.	1.4	0